A Clinical Study on the Treatment of Pulmonary Tuberculosis in a Tertiary Care Hospital in Bangalore, India
Background: Pulmonary tuberculosis (PTB) continues to pose a substantial public health burden in India, which accounts for a significant share of global TB cases. Effective management of PTB is crucial, particularly in urban centers with dense populations and increased transmission risk. This study assesses the effectiveness of standardized anti-tubercular therapy (ATT), evaluates treatment outcomes, and identifies factors influencing therapy adherence and response in a tertiary care setting in Bangalore. Methods: A prospective observational study was conducted from December 2020 to March 2021 involving 200 patients with microbiologically confirmed PTB. Patients received first-line ATT under the Revised National Tuberculosis Control Program (RNTCP). Clinical parameters, demographic data, treatment adherence, and adverse drug reactions were recorded and analyzed using SPSS v25. Follow-ups were conducted monthly, and sputum conversion rates were assessed at the end of the intensive phase (2 months). Results: The cohort had a mean age of 42.5 ± 12.3 years, with a male predominance (62%). Comorbidities included diabetes (18%) and hypertension (14%). At the end of the intensive phase, sputum conversion was achieved in 78% of patients. Overall treatment success rate stood at 85%, while 8% defaulted, and 7% had evidence of drug resistance. Adverse drug reactions were observed in 22%, with hepatotoxicity being the most prevalent. Conclusion: Standardized ATT remains effective for PTB management. However, adverse effects, particularly hepatotoxicity, pose challenges. Continuous monitoring, patient education, and individualized care are essential for improving outcomes and supporting national TB elimination goals.